Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia

• Status: Recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

A total of 100 patients with ST-elevation myocardial infarction (STEMI) presenting slow-flow after primary-percutaneous coronary intervention (PPCI) will be randomized to pharmacologic treatment with hyperemic drugs versus flow-mediated hyperemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fundación EPIC
• Collaborator: Barcicore-Lab

Criteria

Inclusion Criteria:

1. ST elevation myocardial infarction Killip I <12 hours since symptoms onset.

2. ST elevation > 2 mm anterior leads or > 1 mm inferior or lateral leads.

3. Sustained slow coronary flow (TIMI flow 0-2) for at least 30 seconds after stent implantation or stent post-dilatation.

Exclusion Criteria:

1. Previous myocardial infarction in the culprit artery

2. Previous stroke

3. Advanced kidney disease (creatinine clearance <30 ml / min).

4. Active bleeding

5. Allergy to contrast, nitroprussiate or adenosine.

6. Culprit lesion in coronary bypass, left main coronary artery or stent thrombosis

7. Macroscopic thrombus embolization in the infarct-related artery